Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q3 2023 Earnings Call Transcript

Jerry Jabbour: Yes. No, the way LPAD works is not like getting a special protocol assessment. So, LPAD is the termination made at the time of NDA filing, at the NDA approval. It gives the agency the opportunity to look at the totality of the data and our ability to address that restricted patient population. But there are formal feedback to us that were a potential candidate is consistent with what they’ve done for other groups. Currently, there’s only two products approved on LPAD, but that will be a review issue. But certainly, with the design of the study and the target patient population, we fit well within the criteria outlined by FDA to qualify for that. But you don’t expect any sort of declaration in advance. That’s not how it works.

Julian Harrison: Okay, great. Thanks again for taking the question.

Jerry Jabbour: Thanks Julian.

Operator: And once more — I will turn the call back to the speakers for any closing remarks.

Jerry Jabbour: Thanks Chloe. Thanks to everyone for joining us today. We’re thrilled with our FDA update. We’re thrilled with our LNC-docetaxel data. We look forward to additional data clinical disease impact from the small oligonucleotide program. We’ve come a long way in 2023. We’re not done. We’re excited and optimistic about our company’s future and we can’t wait to report additional progress over the next few months. In the meantime, we wish all of our investors and anyone listening to the call, a very happy Thanksgiving holiday. Have a great night and thanks for joining us. Take care.

Operator: This does conclude today’s program. Thank you for your participation. You may disconnect at any time and have a wonderful evening.